Status:
COMPLETED
Evaluation of Tolerability, Efficacy and Adherence to Treatment With Wynzora Cream
Lead Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Brief Summary
The primary objective is to assess with the PPQ questionnaire the patient preference for Wynzora compared with therapy carried out previously with Enstilar spray foam. Secondary objectives Assess sati...
Eligibility Criteria
Inclusion
- Patients older than 18 years of age, of either sex;
- Patients diagnosed with mild-to-moderate psoriasis (PASI and BSA \<10) requiring monotherapy topical with Wynzora;
- Patients who have stopped treatment with Enstilar foam for any reason for at least 30 days; and
- Patients whose medical records are accessible and record all demographic parameters, anthropometric and clinical parameters during the treatment period
- Signature of written informed consent;
Exclusion
- Patients with palmoplantar, inverse, erythrodermic, guttate, and scalp psoriasis.
- Patients who are taking concomitant systemic therapies for psoriasis, such as. cyclosporine, methotrexate, acitretin, phototherapy or biologic therapies.
- Women who are pregnant or planning to become pregnant.
- Patients with disabilities or other motor problems that could complicate self-medication.
Key Trial Info
Start Date :
January 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06180473
Start Date
January 1 2024
End Date
June 30 2024
Last Update
September 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Policlinico Agostino Gemelli
Rome, Italy